Calculus Capital
VC Fund
London, United Kingdom
Calculus Capital is a VC fund in London focused on Biotechnology and Software. At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.
- Total investments:
- 80
- Last investment:
- Lead investor:
- 65%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Calculus Capital invests in
Stages Calculus Capital invests in
Countries Calculus Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.5M–$10M
- Venture - Series Unknown
- $1.9M–$7.8M
Investment Focus
Industry
- Biotechnology 18 (23%)
- Software 10 (13%)
- Medical 8 (10%)
- Health Care 7 (9%)
- Life Science 5 (6%)
Stage
- Funding Round 21 (26%)
- Venture - Series Unknown 18 (23%)
- Series A 11 (14%)
- Seed 9 (11%)
- Series B 4 (5%)
Country
- United Kingdom 51 (64%)
- United States 3 (4%)
- Ireland 1 (1%)
- South Africa 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexandra Lindsay
Investment Director
|
Investment Director | Total investments: 4 | Find email | |
John Glencross
Chief Executive Officer & Co-founder
|
Chief Executive Officer & Co-founder | Total investments: 2 | Find email | |
Richard Moore
Investment Director
|
Investment Director | Total investments: 6 | Find email | |
Robert Davis
Deputy CEO and Head of Portfolio Management
|
Deputy CEO and Head of Portfolio Management | Total investments: 0 | Find email | |
Susan McDonald
Chairman and Co-Founder
|
Chairman and Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Edify Systems
|
Edify is a platform that enables hospitality businesses to streamline their back of house processes and take control of their bottom line. | $2.9M / Seed / Jun 01, 2026 | |
Resurrect Bio
|
Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $10.3M / Series A / Feb 17, 2026 | |
Trogenix
|
Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M / Series A / Oct 06, 2025 | |
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M / Seed / Aug 28, 2025 | |
Laverock Therapeutics
|
Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies. The company builds a platform that uses endogenous microRNA and gene regulatory mechanisms to enable precise, tunable control of gene expression, allowing engineered cells to activate or silence therapeuticfunctions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases. | Seed / Jun 30, 2025 | |
|
Laverock Therapeutics
|
Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies. The company builds a platform that uses endogenous microRNA and gene regulatory mechanisms to enable precise, tunable control of gene expression, allowing engineered cells to activate or silence therapeuticfunctions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases. | Seed / Jun 30, 2025 | |
Booked It
|
Booked It is an online bookings management software that offers innovative customizable technology and creative value-led marketing solutions for the leisure, hospitality, and entertainment industry with | $3.3M / Seed / Apr 15, 2025 | |
Notify Technology
|
Neurophth is a research and development company of gene therapies in ophthalmic disease, which is located in Wuhan Biolake. With Leber hereditary optic neuropathy (LHON) as the breakthrough point, the company has completed the clinical trial of the gene therapy in LHON with the largest sample size in the world, and has explored in the field ofother genetic diseases. The research results have been recognized by a number of national invention patents and PCT. | $1.9M / Venture - Series Unknown / Mar 05, 2025 | |
Invizius
|
Invizius offers extra-corporeal treatments for patients that includes dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. Invizius develops H-Guard, an advanced hemocompatible coating capable of preventing foreign body reactions in the blood at the source. Invizius aims torevolutionize dialysis and other extracorporeal treatments. | $1.3M / Venture - Series Unknown / Sep 23, 2024 | |
Optalitix
|
Optalitix is an award-winning software provider, that offers a no-code pricing and underwriting platform for global insurers, reinsurers, MGAs and lenders. It converts Excel, Python, and R models into cloud-hosted APIs within minutes, enabling compatibility with advanced tools like reserving models and claims simulations, and enhancing efficiencyand innovation in pricing and underwriting. Our products are easy to use. They enable insurers and lenders to manage risks better, with pricing models that can be used everywhere to boost pricing, improve underwriting performance, increase efficiency, and reduce costs. The company's achievements have been recognised by various prestigious programmes, including the Fintech Innovation Lab, Lloyd's Lab, Mass Challenge, and Oxbow Insurtech 25, as well as winning a number of prestigious industry awards | $3M / Venture - Series Unknown / Sep 11, 2024 | |
| See all 80 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Calculus Capital invest in?
Calculus Capital invests primarily in Biotechnology, Software and Medical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 80 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Calculus Capital's check size?
Calculus Capital typically joins rounds of $2.5M–$10M at Series A and $1.9M–$7.8M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Calculus Capital participates in.
How do I contact Calculus Capital?
Public channels for Calculus Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Calculus Capital?
The team at Calculus Capital includes Alexandra Lindsay (Investment Director), John Glencross (Chief Executive Officer & Co-founder) and Richard Moore (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
